Xenon Pharmaceuticals Inc... (XENE)
| Bid | 30 |
| Market Cap | 2.92B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -234.33M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -12.68 |
| Forward PE | -8.45 |
| Analyst | Buy |
| Ask | 41 |
| Volume | 684,334 |
| Avg. Volume (20D) | 680,042.4 |
| Open | 38.20 |
| Previous Close | 38.20 |
| Day's Range | 37.78 - 38.96 |
| 52-Week Range | 26.74 - 46.00 |
| Beta | 1.22 |
About XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...
Analyst Forecast
According to 9 analyst ratings, the average rating for XENE stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 44.05% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call TranscriptXenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a...
